Ying Huang

Director at Quanta Therapeutics.

Raised on Quanta Therapeutics filings

$76.2M

of $89.1M offered across 1 Form D filing

Form D filings: 1
Teammates: 6
Last filing: Jun 24, 2026

Company

Quanta Therapeutics

Biotech · South San Francisco, CA

Oral KRAS G12D and G12V inhibitors for cancer

Oral KRAS G12D and G12V inhibitors for cancer

Investors: 17
Still open: $12.9M

Investors: 17
Sector: Biotech
HQ: South San Francisco, CA

Quanta Therapeutics filings

Quanta Therapeutics Form D filings
Filed	Security	Sold of offered	Filing
Jun 24, 2026	Equity	$76.2M/ $89.1M	Form D/A

EquityFiled Jun 24, 2026Form D/A
$76.2M/ $89.1M

Works with

Also named on Quanta Therapeutics filings

Perry NisenChief Executive Officer, Form D signerForm D signer Cameron PittExecutive Officer, Director Derek MetzgerExecutive Officer Maha KatabiDirector Maria FardisDirector Rajul JainDirector